During the processing the specimens in pathology laboratories, specimens are carefully handled to prevent the occurrence of specimen-related adverse events (SRAEs) such as specimen mix-ups, cross contaminations and other unexpected accidents. These events lead to the specimen misidentification, which might happen in operating theater, endoscopy room or out-patients clinic before the delivery of the samples to the pathology laboratory, or at the pathology department where the specimen is grossly examined, paraffin-embedded or microtoming.

It is not easy to estimate the incidence of SRAE. According to some report, however, it is as high as 0.1-0.5%.[@B1],[@B2] Even in the major hospitals in Europe, the specimen misidentification is confirmed by molecular tests at a rate of 0.5% when all the samples enrolled in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial were examined by DNA profiling methods.[@B3] In the past, human leukocyte antigen typing or blood typing were used for exclusion of identity of multiple samples from the same patients. Recently, however, molecular tests using short tandem repeat (STR) markers have been currently used to detect SRAEs.[@B3]-[@B7] Several STR loci examination are required to get extremely low random match probability (RMP), for which some kits such as AmpFlSTR Identifier PCR Amplification Kit (Applied Biosystems, Carlsbad, CA, USA) and PowerPlex 16 System (Promega, Madison, WI, USA) are commercially available. These commercial kits are used to detect multiple STR loci at least 13 combined DNA index system (CODIS) markers and AMEL (marker of sex determine). Therefore, the combined probability of identity (PI) was extremely low (\<10^-17^). The above-mentioned molecular tests using STR markers are widely used to detect the errors in tissue identification in some laboratories of forensic medicine. But, in Korea, they are not included in the routine laboratory items in hospital practice. They cannot therefore be performed in a convenient and timely manner. Furthermore, they are not reimbursed by the National Health Insurance system. By the way, according to the \"Bioethics and Safety Act\" and \"The Act on Use and Protection of DNA Identification Informations,\" molecular techniques using DNA identification tests are prohibited with some exceptions.

In most of the big pathology laboratories, the microsatellite instability (MSI) test is routinely performed for the screening of the Lynch syndrome. The National Cancer Institute in USA suggested five microsatellite loci[@B8] and most of the pathology laboratories are adopting these loci as specific markers for MSI test. BAT25 is located in intron 16 of *KIT* gene at 4q11-12 and has thymine mononucleotide as a repeating unit. BAT26 is located in exon 5 of *MSH2* gene at 2p22-21 and it has adenine mononucleotide as a repeating unit. D5S346, D2S123, and D17S250 have cytosine-adenine dinucleotide as a repeating unit and they are located in 2p16.3, 5q22-2, and 17q12, respectively.

Our laboratory routinely examines the status of MSI with five microsatellite markers in most of the colon and gastric carcinoma cases. In each case, we retrieve the data and evaluate whether the microsatellite sequences from the normal tissue are practically enough to determine the patient identity.

On the MSI test based on STR loci, the size of peak allele on each locus were different from each other. In our experience, two samples showed different allele locations at least one locus in all the cases in which the specimen misidentification is suspected. On the MSI test, limited STR loci are tested. We cannot therefore rule out the possibility of false-negative results. The false-negative rate based on MSI test is identical to RMP in forensic DNA typing. Before calculating RMP, it is mandatory to examine the allele frequencies at each locus.

Given the above background, we conducted this study to investigate the allele frequency at the STR loci, to calculate RMP and a likelihood ratio (LR) and to estimate the possibility of specimen misidentification on the MSI test.

MATERIALS AND METHODS
=====================

MSI test
--------

To perform MSI test, we differentially marked the tumor and normal mucosa on hematoxylin and eosin staining sections of tissue samples on slide glasses. DNA was harvested from the tissue samples of 10 µm thickness sections which were fixed with either methacarn or formalin and embedded with paraffin after microdissection. Multiplex-polymerase chain reaction (PCR) procedures were performed according to the previously described method ([Table 1](#T1){ref-type="table"}).[@B9] ABI Prism 3100 Genetic Analyzer (Applied Biosystems) and GeneScan v3.7 software (Applied Biosystems) were used to perform the MSI test.

Data analysis and calibration
-----------------------------

We sampled 253 cases of MSI test results that had been reported during the period from April to June 2011. Because an MSI analysis of the tumor DNA may show unstable alleles and two mononucleotide repeat STRs (BAT25 and BAT26) are difficult for identifying exact allele (data not shown), we used the results from the three dinucleotide repeat STR loci (D5S349, D17S250, and D2S123) from normal mucosa for allele frequencies analysis. To estimate the length of nucleotide of each allele, we adopted the local southern sizing algorithm.[@B10] Then we corrected the estimated value of the length of nucleotide lengths and round them off using EXCEL 2010 (Microsoft, Redmond, WA, USA) and R v2.14.0.[@B11] We assumed that there was no \"off-ladder\" allele (the allele that does not fall within 0.5 bp of an allele from the corresponding locus) in 3 microsatellite loci.

Following analyses of raw data, there was a gradual change in the difference between the observed nucleotide length (ONL) and the expected nucleotide length (ENL) in each marker. Nine hundred sixty-nine cases of ONL (969/1518, 63.8%) fell within 0.5 bp of the ENL. It was difficult to apply a single algorithm for general regression to calculate the entire ONL. We therefore calculated regression coefficients of each marker using a linear regression method. Calibration formula was followed as:

Calibrated nucleotide length=ONL-Calculated difference between ENL and ONL=ONL-(Intercept+Slope×ONL)=(1-slope)×ONL-Intercept

Regression coefficients and statistical parameters of D5S346, D17S250, and D2S123 are represented in [Table 2](#T2){ref-type="table"}. Raw and calibrated data are shown in [Fig. 1](#F1){ref-type="fig"}. Following the calibration, only 32 cases of ONL (32/1,518, 2.1%) did not fall within 0.5 bp of the ENL.

Calculation of the random probability and LR
--------------------------------------------

The calculation of the homozygote and heterozygote frequencies in population structure was proposed by National Research Council II (NRC-II) recommendation 4.1. In a general population (inbreeding coefficient, θ=0.01), homozygote and heterozygote frequency were \"p~*i*~^2^+p~*i*~ (1-p~*i*~)θ (p~*i*~; allele frequency)\" and \"2p~*i*~p~*j*~(1-θ) (p~*i*~, p~*j*~; allele frequency),\" respectively. We calculated the LR using a formula: LR=1/RMP.[@B12]

RESULTS
=======

Allele frequencies and statistical parameters in the three microsatellite loci
------------------------------------------------------------------------------

Allele frequencies and statistical parameters of D5S349, D17S250, and D2S123 are represented in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively. At D5S349, 14 alleles with different allele size were identified from the normal tissue of the cancer patients. The frequency of 107 bp allele at this locus was 0.632, which was exceedingly higher than other studies in Korean population.[@B13] The expected heterozygosity (*H*~exp~) and PI at the D5S346 were 0.582 and 0.204, respectively. At the D17S250, there were 12 different sizes of the alleles. Besides, *H*~exp~ and PI of D17S250 were 0.742 and 0.103, respectively. At the D2S128, there were 14 different sizes alleles. Frequency of the highest and the second highest observed allele in D2S128 were 0.277 and 0.164, respectively. Furthermore, *H*~exp~ and PI of D2S128 were 0.847 and 0.044, respectively. Of the three markers, the D2S128 locus has the strongest discriminating power. The combined PI was 9.23×10^-4^ and combined power of exclusion was 0.99908.

According to the above results, we calculated the RMP and LR in all the cases. The LRs were distributed from 136.38 to 5,606,213.10. There was no case of LR\<100. In addition, 56 cases (18.2%) of LR ranging from 100 to 1,000, 107 cases (42.3%) had LR ranging from 1,000 to 10,000, and 100 cases (39.5%) of LR\>10,000. In general, LR of more than 10,000 was regarded as \"very strong evidence to support.\"[@B14] Case 1, 2, and 3 had the lowest LR, the LR of 50 percentile, and the highest LR, respectively ([Table 5](#T5){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}).

Example of SRAE
---------------

The current case is a case suspected of specimen-mix up. The patient was operated for a slowly growing mass at the right parietal lobe of the cerebrum. Five paraffin blocks were made after gross examination, followed by preparation of hematoxylin and eosin slide. Of the 5 slides, one showed quite different histologic features from the others ([Fig. 3A](#F3){ref-type="fig"}). It showed a fibrotic change with infiltrations of the acute and chronic inflammatory cells ([Fig. 3B](#F3){ref-type="fig"} and arrow in [Fig. 3A](#F3){ref-type="fig"}). These histologic features were similar to those of other slides from the same patients. But most of the fragmented tissues were composed of tumor cells with trabecular and nested pattern ([Fig. 3C](#F3){ref-type="fig"}). Tumor cells showed polygonal shape, abundant and eosinophilic cytoplasm, pleomorphic nuclei and an immunoreactivity to anti-hepatocyte antigen. These findings are suggestive of well-differentiated hepatocellular carcinoma. The patient was young and had no history of hepatitis. In addition, the patients had a normal range of alpha-feto protein serologic test. We, therefore, considered the above histopathologic findings as a contamination rather than a metastatic lesion. This was followed by MSI tests to confirm whether the patient actually had hepatocellular carcinoma. But the MSI test results showed that there were differences in the profiles of MSI marker between the different tissue from the same slide ([Fig. 3D](#F3){ref-type="fig"}). This led to a conclusion that the hepatocellular carcinoma tissues were included due to contamination of the tissue samples from other patient.

DISCUSSION
==========

SRAEs are critical errors that might occur in surgical pathology laboratories. If there are any chances that biopsy or cytology specimens are mixed up with each other, this would lead to the resection of normal organ or loss of possibility that patients with cancer might not be treated at the appropriate time. This happens very infrequently in clinical practice, but it is a nightmare of the pathologists and it is not absolutely avoidable. In routine laboratory procedures, there is no practical way to prove or confirm the cross-contamination or shift of the the samples.

It would therefore, be very helpful if the surgical laboratories can set up the method which can be performed in their own laboratory for the screening the personal identity. The methods should be preferably easy and cheap. In the current experimental study, the MSI test based on three dinucleotide markers was effective in screening the personal identity of the patient as compared with other commercially available kit based on three markers (GenePrint STR Systems, Promega). Because we used only three markers for MSI test, our combined PI was lower than that of commercial kits based on multiple markers. Nevertheless, there were no cases of LR of \<100 and about one-third of total cases had LR of \>10,000. This suggest that there is less than 1% of chance that the patients might be different if the two samples showed the same pattern of alleles. In one third cases, this chance is less than 0.01%. In cases of specimen mixed-up, the MSI test can be considered as a successful method for screening the specimen identity.

For the personal identification, some attentions should be paid to the interpretation of allele patterns of the MSI markers. Theoretically, the same allele pattern of the two samples does not always mean that two samples were derived from the same person. If necessary, additional tests using more STR markers should be performed. In most cases, however, we did not have to test more markers to identify the samples. In making a comparison of the allele patterns, pathologic lesion should be avoided not to get ambiguous results. There are two kinds of possibilities that diseased tissue can be disguised as the samples from the different patient. One possibility is that the homozygote locus may be mistaken as heterozygous due to MSI and the other possibility is that the heterozygous locus may be mistaken for homozygous due to a loss of heterozygosity. These types of alterations frequently occur in neoplastic lesions. Not only some types carcinomas but also some dysplastic lesions such as adenomatous lesions of colorectum and dysplasia in Barrett esophagus can be associated with the above alteration.[@B15],[@B16]

Currently, the local southern sizing algorithm is widely used as the standard method for measuring the length of nucleotides. In the current study, however, there was a slight difference between the estimated nucleotide length and reference nucleotide length which showed gradual change in each marker. We recommend to use the calibrated length and conservative interpretation. Sometimes repeat slippage/polymerase stuttering phenomenon was useful for correction.

In conclusion, our results showed that the MSI test are useful to screen the personal identity in case of SRAEs in which the samples are suspected to be mixed up or shifted.
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![(A-C) Boxplots of raw data in D5S346, D17S250, and D2S123, respectively. (D-F) Scatter plot and regression line in each marker. (G-I) Boxplots of the calibrated data in each marker (The X-axis and Y-axis represent the estimated nucleotide length (ENL) and difference between observed nucleotide length and ENL, respectively).](kjpathol-46-131-g001){#F1}

![Results of the GeneScan analysis in case 1, 2, and 3. (A) Case 1. (B) Case 2. (C) Case 3.](kjpathol-46-131-g002){#F2}

![Example of cases of a specimen mix-up. (A) Among the several fragmented specimens, one fragment (arrow) is composed of benign spindle cells and the remaining portions are carcinoma. (B) A high magnification view of the tissue in [Fig. 3A](#F3){ref-type="fig"} (arrow portion). (C) A high magnification view of the carcinoma portion. (D) The result of microsatellite instability test in two different tissues. Upper, GeneScan of benign spindle cell lesion; lower, GeneScan of carcinoma portion. There is a difference between the allele patterns.](kjpathol-46-131-g003){#F3}
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PCR primers for the microsatellite instability test
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Regression coefficients and statistical parameters in three loci: D5S346, D17S250, and D2S123
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###### 

Size of alleles and allele frequencies in D5S349, D17S250, and D2S123
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Minimum allele frequency: 0.010 (When allele frequencies of estimated nucleotides length fall below the minimum allele frequency, then the minimum allele frequency is used instead).

###### 

Statistical parameters in D5S349, D17S250, and D2S123
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^a^Expected heterozygosity; ^b^Polymorphism information content (the probability that a given offspring of a parent carrying a rare allele at a locus will allow deduction of the parental genotype at the locus); ^c^Power of discrimination (defined as PD=1-PI); dProbability of identity (matching probability, the probability that two individuals selected at random will have an identical genotype at the tested locus).
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Examples of random match probability and likelihood ratio in each allele
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RMP, random match probability; LR, likelihood ratio.

^a^Homozygote.
